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The prognosis of patients with gastric cancer (GC) is
guarded; while endoscopic or surgical resection is cura-
tive in about 90% of patients with early-stage (T1N0)
GC, survival decreases dramatically for patients with
T2-3 GC or those with regional lymph node involve-
ment [1], especially in Caucasian patients. Interestingly,
stage by stage, Asian patients with T2 and T3 GC have a
significantly better prognosis than non-Asian patients
[2]. The histological phenotype appears to matter for
patient’s prognosis and patients with diffuse type GC
have less favourable outcomes. Although several mo-
lecular classifications of gastro-oesophageal junction
(GEJ) and GC have been described [3,4], these do not
yet contribute to standard patient management de-
cisions (see Fig. 1).
In addition to tumour biology, the quality of surgery
and perioperative multidisciplinary management,
including perioperative or adjuvant chemotherapy, are
major determinants of patients’ short-term and long-
term outcomes. In Europe, perioperative chemo-
therapy is standard of care for medically fit patients
with clinical stage II-III GC and is recommended in
current guidelines [5,6]. In contrast, in Japan, GC pa-
tients are usually treated with surgery followed by
adjuvant chemotherapy in patients with pathologically
confirmed stage II or III GC. Both, European and
Japanese Guidelines [5,7] currently agree that surgery
should be performed as a D2 resection in high volume
centres.
2. Summary of treatment approaches and challenges in
Europe and Japan
The standard of care in Europe has recently changed
because of the results of the phase III randomised FLOT4
trial [8], in which perioperative chemotherapywith FLOT
(5-fluouracil [5-FU], leucovorin, oxaliplatin and doce-
taxel) was associated with a significant improvement in
overall survival (median survival: 35 versus 50 months;
projected 5-year survival: 36 versus 45%) compared with
ECF/ECC (epirubicin, cisplatin and 5-FU/capecitabine).
Thus, perioperative chemotherapywith FLOThas a clear
incremental benefit compared with anthracycline-based
perioperative chemotherapy and is now considered Eu-
ropean standard of care for patients with locally
advanced (resectable) GC. Nevertheless, some clinical
challenges remain; for example, more than 40% of pa-
tients treated with neoadjuvant FLOT had either a min-
imal or no histopathological response to neoadjuvant
chemotherapy (tumour regression grade [TRG] IIIaccording to Becker [9]) or were unable to proceed to
surgery, most often because of progressive disease.
Furthermore, there are concerns with respect to the
suitability of elderly patients or patients with co-
morbidities for triplet chemotherapy regimens in gen-
eral in view of their higher toxicity profile. A final chal-
lenge is that there are still patients who have a poor
prognosis following perioperative chemotherapy plus
surgery, such as patients with incomplete (R1) resections
or lymph node metastases [10] indicating an urgent need
for further research.
In Japan, the standard of care for patients with stage
II or III GC results from the pivotal phase III ‘ACTS-
GC’ study, which demonstrated the efficacy of adjuvant
S-1 chemotherapy after D2 surgery in Japanese patients
[11,12]. In patients with pathological stage II disease, 5-
year survival was over 85% in patients treated with
surgery followed by 1 year of S-1 chemotherapy. The
question whether the duration of adjuvant S-1 treatment
in patients with p-stage II GC can be reduced from 8 to
4 cycles without compromising efficacy was recently
investigated in the randomised phase III JCOG1104-
trial [13]. However, the non-inferiority (NI) of four
versus eight courses of S-1 could not be demonstrated.
Thus, 1 year of adjuvant S-1 chemotherapy in patients
with p-stage II GC remains the standard of care in
Japan. Several years after ACTS-GC, the Korean
‘CLASSIC’-trial [14] demonstrated a survival benefit for
GC patients treated with surgery followed by adjuvant
capecitabine and oxaliplatin (CAPOX) compared with
surgery alone and established CAPOX as an alternative
to adjuvant S-1 chemotherapy in Korea and Japan.
The more recent randomised phase III JACCRO-07
trial demonstrated that patients treated with S-1 plus
docetaxel compared with S-1 alone as adjuvant treat-
ment for curatively resected GC had improved 3-years
relapse-free survival (65%) compared with patients
treated with S-1 alone (49.6%, hazards ratio [HR] 0.632,
95% confidence interval [CI] 0.400e0.998, p Z 0.0007)
[15]. On this basis, S-1/docetaxel after D2 gastrectomy is
expected to become a new standard of care for patients
with stage III GC in Japan.
Although the use of neoadjuvant chemotherapy
(NAC) is uncommon in Japan, even for locally
advanced GC, there has been recent research in this
area. JCOG0501 [16] examined the value of neo-
adjuvant S-1 plus cisplatin followed by
surgery þ adjuvant S-1 versus surgery þ adjuvant S-1 in
Borrmann type 4 (diffusely infiltrative) or large (8 cm)
Borrman type 3 (ulcero-infiltrative) cancers. Interest-
ingly, 3-year overall survival did not appear to be
different between the two arms of the trial (60.9% versus
62.4% for patients treated with or without NAC, HR
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Fig. 1. Summary of patient flow and factors influencing treatment outcomes in stage II and III GC.
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lection of cases and the NAC regimen used might be
reasons for the lack of success of this approach. Ac-
cording to a subgroup analysis of this trial [17], NAC
might be beneficial for cancers with non-poorly cohesive
type GC.
Based on the results of a recent observational study
in Japan, which examined the accuracy of computed
tomography (CT) and oesophageal ultrasonography
for preoperative staging, there are concerns that pa-
tients with early disease might be overtreated with
NAC: The positive and negative predictive value of an
endoscopic or CT diagnosis of cT3-4 disease to detectpT3-4 GC were 79.2% (95% CI 76.2e81.9) and 59.2%
(95% CI 54.3e63.9) in this trial. Additional imaging
options such as endoscopic ultrasound or 1 mm slice
CT could not improve these results (JCOG1302A) [18].
Considering the incidence of p-stage I and the magni-
tude of the potential benefit of NAC for p-stage III,
JCOG decided to include patients with cT3-4, cN1-3
GC (corresponding to clinical stage III and IVA in the
8th edition of the UICC TNM classification) in the
ongoing phase III JCOG1509-trial investigating the
superiority of NAC with S-1 plus oxaliplatin followed
by surgery and adjuvant S-1 over surgery followed by
adjuvant S-1.
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Special populations, such as elderly patients, are usually
inadequately represented in clinical trials.
For example, the ACTS-GC trial excluded patients
aged over 80 years, and thus, it is unclear whether the
evidence from this trial can be generalised to this patient
group.
Moreover, several studies showed that renal
dysfunction and sarcopenia, frequently observed in
elderly patients, are risk factors for early termination of
S-1 treatment because of adverse events. Both, EORTC
and the International Society of Geriatric Oncology
[19,20] have suggested that trials specifically recruiting
elderly or frail patients should be conducted. The
recently presented phase III GO2 trial [21] was designed
to find the optimum doses of capecitabine/oxaliplatin
(CAPOX) in patients with advanced gastroesophageal
adenocarcinoma not suitable for standard full dose 3-
drug chemotherapy, mostly because of age or frailty.
This trial demonstrated NI in terms progression-free
survival (PFS) for 60% of the full dose of cap/ox (oxa-
liplatin 130 mg/m2 and capecitabine 625 mg/m2 twice
daily from day 1e21 every 3 weeks). Furthermore, the
overall treatment utility, a composite end-point
including clinical benefit, tolerability, quality of life
and patient value, was better using this reduced dose
level compared with full dose cap/ox. Both results
confirm the importance of specific trials for the elderly
population, as well as their potential to improve treat-
ment outcomes for this population.
A survey conducted by JCOG among 58 partici-
pating institutions revealed that only a minority of
elderly patients are able to receive the full dose of S-1
adjuvant chemotherapy and that surgery alone is
considered standard of care for elderly patients by the
community [22]. On this basis, the ongoing JCOG1507
trial is designed to confirm the superiority of adjuvant
treatment with a reduced dose of S-1 for vulnerable
elderly patients (80 years old or older) treated with
D1þ/D2 gastrectomy compared with surgery alone. A
detailed description of the inclusion criteria including
definitions for vulnerability and frailty has been pub-
lished [22].4. The EORTC and JCOG collaboration: shared
challenges and goals
EORTC and JCOG believe in international, multidis-
ciplinary collaboration [23,24] including surgery, medi-
cal oncology, pathology, gastroenterology, endoscopy,
radiology, nuclear medicine, radiotherapy and biosta-
tistics to further improve treatment outcomes for pa-
tients with GEJ and GC.Current key challenges: the perspective of EORTC
and JCOG.
1. The limited precision of clinical staging, especially for
lymph node staging, including the impossibility to exclude
peritoneal carcinomatosis without invasive laparoscopy.
2. The heterogeneity of GC with respect to molecular and
histopathological subtypes and development of appropriate
treatment strategies according to subtype.
3. The development and validation of biomarkers, including
liquid biopsies.
4. The toxicity of standard of care perioperative/adjuvant
chemotherapy.
5. The development of evidence-based treatment strategies for
special populations, such as elderly and frail patients.
6. The improvement of surgical quality assurance, as well as
standardisation and quality assurance of multidisciplinary
perioperative management and supportive care
7. The development of validated surrogate end-points for
clinical trials.
The JCOG and EORTC trials are designed to address
these major clinical and translational research chal-
lenges and are expected to have a significant impact on
future GC patient management. The identification of
molecularly, histopathologically and/or clinically
defined subtypes, the integration of targeted-therapies
and immunotherapies, with or without neoadjuvant
radiotherapy into state-of-the-art perioperative chemo-
therapy, and the development of rational and specific
treatment strategies is in our view the best way to move
the field forward and improve patient outcomes.
4.1. Integrating immunotherapy into EORTC/JCOG
gastric cancer trials
Immunotherapy has been transformative in diseases
such as metastatic melanoma [25] and is one of the key
themes in our groups’ work [26]. Several trials of anti-
PD1 therapy have demonstrated modest efficacy in
GC [27] and raised hope that immune checkpoint
blockade alone or in combination with chemotherapy or
other immune modifying agents may improve outcomes
of selected patients with GC [28e30]. Keynote-62
(NCT02494583) [31] presented at ASCO 2019 rando-
mised 763 patients with a PD-L1 combined positive
score  1 [32] to either first-line palliative chemotherapy
with cisplatin and 5-FU or capecitabine alone versus the
same chemotherapy combined with pembrolizumab or
pembrolizumab alone. Within a NI limit of 1.2, pem-
brolizumab alone was not inferior compared with
cisplatin/5-FU for the primary end-point overall sur-
vival (OS) and improved survival in patients with com-
bined positive score (CPS)  10. However, the
combination of chemotherapy plus pembrolizumab
compared with chemotherapy alone was not superior for
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these results will result in an approval for pem-
brolizumab as first-line treatment in any subgroup of
patients is currently under discussion. Of note, while
chemotherapy with cisplatin/5-FU, which was used as
the comparator and backbone in this trial, has been an
internationally accepted standard for more than a
decade, in 2019 it is neither the most effective nor the
best tolerated chemotherapy regimen for advanced GC.
Thus, at this moment in time, chemotherapy will
remain standard of care for the majority of patients with
GC and the identification of predictive biomarkers re-
mains one of the biggest challenges: While DNA
mismatch repair deficiency, resulting in microsatellite
instability (MSI-high), predicts the response to immu-
notherapy in multiple solid tumours including GC [33],
Epstein-Barr-Virus (EBV) infection may further predict
response to immune checkpoint inhibition [34]. How-
ever, the percentage of patients with these GC subtypes
is relatively low, response to immune checkpoint inhi-
bition may not be limited to these patients and not all
patients with MSI-high or EBV positive tumours
respond to immunotherapy. Especially the role of
tumour mutation burden and extent of tumour infil-
trating lymphocytes needs further investigation in this
context. Patients treated according to the European
standard with platinum-fluoropyrimidineebased peri-
operative chemotherapy plus surgery [5,6], who have
lymph node metastases after neoadjuvant chemotherapy
have a very poor prognosis [10]. For these patients,
EORTC is currently initiating a trial (EORTC-1707
VESTIGE; NCT03443856) investigating adjuvant anti-
PD1 plus anti-CTLA4 therapy. Patients with MSI-
high GC appear to have consistent response rates of
>50% to anti-PD1 therapy but do not appear to benefit
from standard perioperative chemotherapy [35], while
patients with microsatellite stable GC might benefit
from a combination of immunotherapy and chemo-
therapy. To this end, another EORTC trial investigating
immunotherapy for resectable MSI-high GC is in
preparation.
4.2. Integrating targeted therapies
Several recent attempts to integrate targeted therapies
(e.g. bevacizumab [36], panitumumab [37]) into periop-
erative treatment of GC patients have not been able to
demonstrate survival benefits in unselected patient
populations.
At present, the only validated predictive biomarker in
GC is the HER2 status [38,39]. For patients with HER2-
positive, locally advanced, unresectable or metastatic
disease [39], the addition of trastuzumab to fluoropyr-
imidine/cisplatin chemotherapy [38] is an international
standard-of-care treatment. However, the clinical
impact of HER2 targeting therapies in early GC is un-
known. Both, EORTC and JCOG are convinced thatintroducing molecular targeting agents in patients
selected on the basis of a predictive biomarker is a
promising strategy for tailored adjuvant or neoadjuvant
therapy and consider the investigation of the role of
HER2 targeting treatments in early GC as a major
challenge. EORTC 1203, the INNOVATION-trial
(NCT02205047) [40], an intergroup collaboration of
EORTC with the Dutch Upper GI group, Korean
Cancer Study Group and surgical quality assurance
done by JCOG, addresses the question whether the
integration of trastuzumab, with or without pertuzu-
mab, into perioperative chemotherapy improves histo-
pathologic response rate (primary end-point), PFS and
OS in locally advanced resectable (clinical stage Ib-III)
HER2 positive GC. The ‘TRIGGER’ study (JCOG
1301C) [41], a randomised phase II trial evaluating the
efficacy of neoadjuvant trastuzumab for patients with
HER2-positive GEJ or GC with extensive lymph node
metastases, addresses a complementary question to the
EORTC-1203 ‘INNOVATION’-trial. A collaboration
between JCOG and EORTC on the histopathological
reporting of the resection specimen after neoadjuvant
treatment is ongoing.
4.3. Biobanking and translational research
The multiple histological and molecular classifications
described reflect the intertumoural heterogeneity of GC.
However, significant intratumour heterogeneity of bio-
markers also exists, which is a challenge for develop-
ment of novel therapies (for review see Refs. [42,43]).
With the exception of microsatellite instability [44] and
HER2 [38] in advanced GC and the histological subtype
in early GC to assess the suitability for endoscopic
resection [45], none of the published classifiers are
currently used in routine clinical practice. We consider
the collection of high-quality biospecimens including
but not limited to tissue, blood (‘liquid biopsies’), body
fluids, images (CT, magnetic resonance imaging, posi-
tron-emission tomography), linked to high quality clin-
ical and pathological data from all trials mandatory for
advancing personalised treatment using next generation
‘omic’ technologies (genomic and/or transcriptomic
sequencing, proteomics, metabolomics, etc.),
morphology-based methodology (multiplex immuno-
histochemistry, in situ hybridisation), as well as deep
learning approaches (‘Histiomics and Radiomics’). As
nearly all contemporary high-throughput investigations
on tissue samples involving DNA or RNA can be per-
formed using routine formalin-fixed paraffin embedded
(FFPE) material from endoscopic biopsy or resection
specimens, we mandate FFPE tissue collection in all
prospectively developed trials. We already provide
detailed guidance on specimen workup and material
collection to the local pathologists in the EORTC 1203
trial. In addition, central pathology review of pretreat-
ment biopsies and resected specimens by experienced
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thology data of our groups’ trials. Being faced with
substantial heterogeneity of GC and neoadjuvant ther-
apy being standard of care in Europe, investigating
endoscopic biopsies poses a significant challenge with
respect to the question whether the sample is represen-
tative of the tumour as a whole. Existing guidelines on
where and how often to biopsy are currently limited to
HER2 testing [46e49]. Liquid biopsies sampling circu-
lating tumour cells or DNA or other compartments of
tumour cells are far less invasive than tissue biopsies and
can relatively easily be performed at various different
time points during treatment or at disease progression.
Whether investigations using liquid biopsies are able to
improve the selection of patients for targeted or other
treatments is an open question at this moment in time.
EORTC strives to collect liquid biopsies within current
and future trials to explore their potential clinical utility.
Investment in infrastructure and a central EORTC
biobanking facility (https://www.ibbl.lu), quality
accredited according to ISO 9001, compliant with the
principles of NF S96-900 certification and robust gov-
erning principles will ensure appropriate acquisition,
storage and annotation of biospecimens and facilitate
their optimal use. JCOG has also initiated a biobank
project for clinical trials, which started with the collec-
tion of blood samples but recommends tissue bio-
banking as well. Of note, validation of biomarkers
across different populations (e.g. East versus West or
male versus female gender) will be crucial for designing
and understanding the results of international trials. As
a first step, the central histopathology review in the
EORTC 1203 and the JCOG TRIGGER [41] trial will
be performed in a standardised manner between Japa-
nese and European pathologists to facilitate a pooled
analysis of both trials. Both are excellent examples of
the collaboration between JCOG and EORTC.
4.4. Integrating radiotherapy into future EORTC GC
trials
In contrast to JCOG, where radiotherapy is not
considered for gastrointestinal cancers (except patients
with oesophageal squamous cancer), EORTC as a
multidisciplinary academic group sees the development
of combined modality treatment regimens, which inte-
grate radiotherapy into systemic treatment across dis-
eases as major challenge and strategic axis. Especially in
gastrointestinal cancers, pivotal EORTC trials in rectal
[50] and anal [51] cancers defined international stan-
dards of care for the last decades. Two recent trials
demonstrated disappointing results for postoperative
chemoradiation in patients with GC:
1. ‘CRITICS’ [52], which showed no benefit for postoperative
chemoradiotherapy, as compared with postoperative
chemotherapy after preoperative chemotherapy with ECF.2. ARTIST-2 [53], conducted in Korea, which randomised
stage II/III, node-positive, D2-resected GC to receive 1 year
of adjuvant S-1 versus SOX (S-1/oxaliplatin) for 6 months
or SOX plus radiotherapy (45 Gy) and did not show any
difference in disease-free survival between SOX and SOX/
radiotherapy.
Nevertheless, the EORTC GC task force considers
several major questions regarding the use of radio-
therapy in the perioperative management of GEJ and
GC still open:
First, is there a role for the integration of radio-
therapy in the neoadjuvant component of perioperative
chemotherapy? This question is being investigated in the
EORTC supported ‘TOPGEAR’etrial (NCT01924819)
[54].
Second, which patients benefit from radiotherapy? As
a consequence of differences in anatomy and disease
biology, the rationale to integrate radiotherapy may be
stronger in GE junction cancers compared with GC.
Owing to their reduced anatomic mobility, radiation
volumes can be smaller, which improves the tolerance
and decreases off-target side effects. Further important
questions regarding radiotherapy include the evaluation
of technical progress in radiotherapy, such as high pre-
cision, high field, MRI-guided radiotherapy, to allow a
fully adaptive treatment, which takes organ filling and
motion into account.
The third major question, and perhaps the most
interesting one for the future, concerns the immune
stimulatory effect [55] of radiotherapy and whether it is
possible to integrate radiotherapy in current multimodal
treatment regimens to fully exploit its potential to
enhance the benefit of immunotherapy.5. Surgical quality assurance
In contrast to drug treatment, which may easily be
standardised, surgery is an individually manufactured
intervention, highly variable according to expertise and
technique, and has therefore not been considered as
suitable for randomised controlled trials (RCTs) for a
long time. Only at the end of the 20th century and de-
cades after their development in medicine, RCTs have
been introduced in surgery. Since then, they allowed for
significant progress and permitted to establish high-level
evidence in many surgical fields. The quality of surgery,
especially regarding key elements, such as lymph node
dissection, has a major impact on the individual patients
and trial outcome. To standardise and improve the
quality of surgery in surgical and multimodal trials,
surgical quality assurance (QA) is of major importance
[56]. Surgical QA has many issues to be discussed: In
clinical trials, credentialing of surgeons before enrol-
ment, standardisation of surgical techniques and moni-
toring of surgical performance all have a positive effect
on the quality of a RCT. Surgeons participating in
Table 1
Current EORTC and JCOG trials on perioperative treatment of gastric cancer.
EORTC
22114 EORTC-22114-4011-GITCG-ROG-TOPGEAR: Trial of preoperative therapy for gastric and oesophagogastric junction
adenocarcinoma. A randomised phase II/III-trial of preoperative chemoradiotherapy for resectable gastric cancer https://
clinicaltrials.gov/ct2/show/NCT01924819
1203 EORTC-1203-GITCG-INNOVATION: INtegration of trastuzumab, with or without pertuzumab, into periOperatiVe
chemoTherapy of HER2 posiTive stOmach caNcer: The INNOVATION-trial https://clinicaltrials.gov/ct2/show/NCT02205047
1707 EORTC-1707-GITCG-VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative
chemotherapy and high risk for recurrence (Nþ and/or R1)dan open-label randomised controlled phase II-study (not yet
recruiting) https://clinicaltrials.gov/ct2/show/NCT03443856
JCOG
1104 JCOG 1104: Optimal period of adjuvant S-1 chemotherapy for pathological stage II gastric cancer patients who underwent D2
gastrectomy: OPAS-1 phase III https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?
functionZbrows&actionZbrows&typeZsummary&recptnoZR000008210&languageZJ
0501 JCOG 0501: Randomised phase III trial of surgery plus neoadjuvant TS-1 and cisplatin compared with surgery alone for type 4
and large type 3 gastric cancer https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?
functionZbrows&actionZbrows&recptnoZR000000356&typeZsummary&languageZJ
1301C JCOG 1301C: A randomised phase II study of systemic chemotherapy with and without trastuzumab followed by surgery in
HER2 positive advanced gastric or oesophago-gastric junction adenocarcinoma with extensive lymph node metastasis: Trigger
study https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?
functionZbrows&actionZbrows&typeZsummary&recptnoZR000018667&languageZJ
1507 JCOG 1507: A phase III trial to confirm S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric
cancer patients who underwent gastric resection: BIRDIE https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?
recptnoZR000029398
1509 JCOG 1509: Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2
gastrectomy with adjuvant S-1 in locally advanced gastric cancer: NAGISA trial https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_
view.cgi?recptnoZR000027564
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number of interventions, depending on the procedure.
Furthermore, surgical techniques have been stand-
ardised in detail based on the discussion of videos from
experts, and operative pictures are monitored on a reg-
ular basis. EORTC is facing this challenge by collabo-
rating with JCOG and the European Society of Surgical
Oncology (ESSO) in the surgical research QA platform
named SURCARE [56] (http://www.eortc.org/quality-
assurance/surgery/). The main purpose of SURCARE
is to develop better surgical oncology trials and
establish an integrated approach to ensuring high QA
standards in surgical clinical research in Europe and
globally. SURCARE advocates the development of a
standard surgical QA process, which includes
credentialing, standardisation of technique and
assessment, as well as central monitoring.
Furthermore, SURCARE aims to facilitate
engagement of young surgeons in international and
multidisciplinary clinical research through research
fellowships. SURCARE has been adopted for the
surgical QA of the EORTC-1203 ‘INNOVATION’
trial: Independent surgeons and pathologists from
JCOG and EORTC will conduct a central review of
intraoperative photographs and macroscopic pictures of
the resected specimens to assess the completeness of the
surgical treatment. Furthermore, data from surgical and
pathology case report forms and 30-day and 90-day
surgical complications graded by Clavien-Dindo classi-
fication [57] will be documented and analysed.6. Challenges in trial design
To increase the efficacy of drug development, ‘platform’
and adaptive randomisation designs such as e.g. I-SPY 2
in breast cancer [58] or non-Bayesian alternatives
(MAMS platform trials) [59] as e.g. NCI-MATCH
(https://www.cancer.gov/about-cancer/treatment/
clinical-trials/nci-supported/nci-match) or FOCUS4
(http://www.focus4trial.org/) in colorectal cancer have
been developed. Furthermore, moving towards
seamless phase II/III trials with best treatment arm or
target population selection and sample size re-
estimation based on early observed treatment
difference [59,60] helps to shorten the development. In
addition, it uses resources more efficiently by avoiding
restarting the accrual for the phase III trial. Finally,
with modern perioperative treatment of GC, at least
half of all patients will be long-term survivors. While
our trials aim at increasing this percentage, the
EORTC survivorship research protocol YOU-(Your-
Outcome-Update) [61] presents a unique opportunity
to assess the causal relationship between treatment and
long-term outcomes because of the high quality
registration of treatment details in the EORTC clinical
database. In addition to physical issues, YOU also
collects data on the psychological and socio-economic
well-being among long-term survivors (http://www.
eortc.org/other-research-initiatives/survivorship-
outcome/). Whenever possible, patients will be included
in this protocol. Apart from the ongoing interventional
A.D. Wagner et al. / European Journal of Cancer 124 (2020) 67e7674trials listed below, an update and validation of the GC-
specific EORTC-QLQ-STO 22 quality-of-life
questionnaire module [62], which includes interviews
with both GC patients and healthcare professionals, is
ongoing in collaboration between JCOG and EORTC.
EORTC, European Organisation for Research and
Treatment of Cancer; JOCG, Japan Clinical Oncology
Group.
In conclusion, despite different standards and out-
comes for patients with GC between Europe and Japan,
EORTC and JCOG share their view of challenges, goals
and a vision for future clinical trial design and ques-
tions. Both collaborative and complementary projects
between both groups are ongoing, and future activities
of both groups are coordinated in regular meetings (See
Table 1).
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